Smart science to improve lives™
Croda Denmark

Denmark

Croda Denmark was formerly Brenntag Biosector (Biosector), acquired in 2019 and for more than 80 years has been dedicated to safe and effective adjuvants for use in human and veterinary vaccines. No other company can match our expertise in this area.

Our site at Frederikssund includes R&D, engineering, production QA/QC, administration, warehouse and distribution: 

  • World leading adjuvant specialist serving major human and veterinary vaccine producers
  • Industry leading R&D capabilities for a strong pipeline of innovative next generation vaccine adjuvants
  • Running the only aseptic and GMP certified manufacturing site for adjuvants globally

The combination of a passionate team, adjuvant expertise, industry-leading production facilities and a dedicated global sales network committed to understanding customer needs mean we can better serve our pharmaceutical customers through our classic portfolio and our rich development pipeline. We realise the vaccines and blood products of tomorrow require new and innovative adjuvants, so our R&D department is focused on the next generation of adjuvants.

Croda Denmark

Elsenbakken 23
3600 Frederikssund
Denmark
sustainable innovation plants in a lab

About us

We are the name behind high performance ingredients and technologies in some of the most successful brands in the world.

Croda Formulator at work in labs

Where we operate

Every day our global team, across 37 countries, work together to inspire our customers.

Further reading

Excellent first half performance driving profit growth

Excellent first half performance driving profit growth

Read more

Croda joins the World Business Council for Sustainable Development

Croda International Plc, the company that uses smart science to create high-performance ingredients and solutions that improve lives, has today joined over 200 of the world’s leading sustainable...

Read more
Louisa Burdett

Jez Maiden to retire as Croda Group Finance Director; Louisa Burdett appointed as successor

7 November 2022: Jez Maiden, Group Finance Director, will be retiring from the Company during 2023 after eight years in the role, Louisa Burdett has been appointed to succeed Jez.

Read more
Vaccine syringe

Pharma investor seminar

Empowering biologics delivery in Pharma

Read more